ArticleNature communications2025
Impact of HLA evolutionary divergence and donor-recipient molecular mismatches on antibody-mediated rejection of kidney allografts.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of HLA Evolutionary Divergence and HLA Donor-recipient Molecular Mismatches on Kidney Allograft Rejection: a Population-based Study
Prognostic Value of HLA Eplet Mismatches for Long-term Kidney Transplant Outcomes
Who cites it
6 citing papers in PubMed.
- Association of eplet mismatch load and allograft injury in kidney transplant recipients.Clinical kidney journal · 2026Article
- A multicenter kidney transplantation study identifies hierarchy and directionality of HLA-DQ alloimmune responses.Nature communications · 2026Article
- Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy.EMBO molecular medicine · 2026Article
- Association of PIRCHE scores and allograft injury in kidney transplant recipients.Frontiers in immunology · 2026Observational
- Clinical application of PIRCHE scores: reclassifying immunologic risk in patients with medium eplet mismatch.Frontiers in immunology · 2026Article
- The application of genetic testing technology in kidney transplantation: precision matching, non-invasive monitoring and personalized management.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several in-silico methods emerge to assess HLA immunogenicity and stratify immunological risk, including HLA molecular mismatches and HLA evolutionary divergence (HED). However, their added value in risk-stratifying antibody-mediated rejection (AMR) remains uncertain. We include 5159 kidney transplant recipients from four centers. Thirty-three clinical and immunological parameters are assessed, including HLA eplet mismatches, PIRCHE-II scores, and HED. Their associations with AMR are evaluated using Cox models. AMR occurrs in 1024 patients (19.9%). Immunological determinants of AMR include anti-HLA DSA (MFI:500-1400, HR:1.87; MFI > 1400, HR:3.84, p < 0.001) and HLA Class II eplet mismatches (HR:1.02, p < 0.001). HLA-DQB1-derived (HR:1.01, p = 0.005) and HLA-DRB1-derived PIRCHE-II scores (HR:1.01, p = 0.001) are also associated with AMR, while HED is not. These findings remain consistent across centers and subpopulations, including non-sensitized patients (n = 4137). Our findings show that Class II molecular mismatches are independently associated with AMR. HED shows no association, suggesting limited utility for immune-risk stratification at a population level. Clinicaltrials.gov: NCT06436586.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.